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Abstract
Background: Calprotectin is a calcium-binding cytoplasmic protein found in neutrophils and increasingly used as a marker
of bowel inflammation. Fecal occult blood (FOB) is also a dependable indicator of bowel morbidity. The objective of our
study was to determine the applicability of these tests as surrogate markers of Schistosoma mansoni intestinal morbidity
before and after treatment with praziquantel (PZQ).
Methods: 216 children (ages 3–9 years old) from Buliisa District in Lake Albert, Uganda were examined and treated with PZQ
at baseline in October 2012 with 211 of them re-examined 24 days later for S. mansoni and other soil transmitted helminths
(STH). POC calprotectin and FOB assays were performed at both time points on a subset of children. Associations between
the test results and infection were analysed by logistic regression.
Results: Fecal calprotectin concentrations of 150–300 mg/g were associated with S. mansoni egg patent infection both at
baseline and follow up (OR: 12.5 P= 0.05; OR: 6.8 P= 0.02). FOB had a very strong association with baseline anemia (OR: 9.2
P= 0.03) and medium and high egg intensity schistosomiasis at follow up (OR: 6.6 P= 0.03; OR: 51.3 P= 0.003). Both tests
were strongly associated with heavy intensity S. mansoni infections. There was a significant decrease in FOB and calprotectin
test positivity after PZQ treatment in those children who had egg patent schistosomiasis at baseline.
Conclusions: Both FOB and calprotectin rapid assays were found to correlate positively and strongly with egg patent S.
mansoni infection with a positive ameloriation response after PZQ treatment indicative of short term reversion of morbidity.
Both tests were appropriate for use in the field with excellent operational performance and reliability. Due to its lower-cost
which makes its scale-up of use affordable, FOB could be immediately adopted as a monitoring tool for PC campaigns for
efficacy evaluation before and after treatment.
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Introduction
With over 207 million people worldwide infected with schistoso-
miasis, mostly in sub-Saharan Africa, there is still a pressing need to
optimize field-appropriate tools for morbidity staging and monitor-
ing of clinical disease [1]. In recent years there has been a scale-up of
schistosomiasis control programs worldwide [2,3]. However, no
single direct morbidity marker has been adopted to monitor the
clinical impact of these interventions [4]. Part of the difficulty is due
to the variability of schistosomiasis-related clinical manifestations
that are often non-specific and species dependent. This holds
particularly true for intestinal schistosomiasis, mainly caused by two
different species of the genus Schistosoma: S. japonicum and S. mansoni,
in which the clinical diagnostic gold-standard for bowel morbidity is
a colonoscopy. This has limited applicability in resource limited
settings owing to logistic constraints [5]. Hence it is important to find
suitable low-cost reliable proxy markers of bowel morbidity that can
aid in measuring the clinical impact of control programs.
Intestinal schistosomiasis is an inflammatory disease in which
the observable pathology derives from the local inflammatory host
response to the egg-entrapment inside the intestinal mucosa and
submucosa [5]. It can manifest with a wide range of symptoms
depending on the extent of the inflammation and friability of the
mucosa, ranging from intermittent abdominal pain to overt acute
dysentery. By performing colonoscopy studies, colorectal schisto-
somiasis has been consistently associated with findings of intestinal
polyps and pseudopolyps that can present as blood-per-rectum in
affected individuals [6].
Across community-based surveys worldwide, detection of
intestinal blood loss in schistosomiasis-endemic areas has revealed
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a positive association between egg-patent infection and presence of
blood in stools [7–9]. However, the majority of these studies used
guaiac-based fecal occult blood (FOB) tests that are known to be
less sensitive than the FOB immunochemical assays now widely
used for colorectal cancer detection [10,11]. FOB has also been
used for identifying blood loss in parasitic enteric infections with
hookworm, Trichuris trichiura or Entamoeba histolytica [12–14]. For
intestinal schistosomiasis a longitudinal FOB study in Ugandan
children treated with praziquantel (PZQ) showed a strong
correlation with infection before and one year after intervention,
highlighting its potential use as a morbidity marker across field
surveys [15,16]. Shorter term disease dynamics need investigation,
in particular during the standard cure rate monitoring period at 24
days post PZQ treatment [17].
Calprotectin is a neutrophil cytoplasmic calcium-binding
protein that is also found in monocytes and early stage
macrophages. Its degranulation inside the intestinal lumen occurs
as a response to local inflammation [18]. Detection of calprotectin
in stool is currently used across gastroenterology practices to aid
diagnostically in distinguishing between inflammatory bowel
disease and other non-inflammatory ailments, thereby decreasing
the number of unnecessary endoscopies performed. It is also used
as a validated marker for disease activity and response to treatment
[19–21]. Its use in enteric infections is gaining recognition,
particularly as a correlative marker for clinical severity in
infectious diarrhea from both viral and bacterial etiologies [22].
Based on its potential as a surrogate inflammatory maker, we had
previously hypothesized that fecal calprotectin could be elevated in
schistosomiasis-associated intestinal pathology. However upon
field-testing of an enzyme-linked immunosorbent assay, we found
no correlation with S. mansoni infection [16]. The study was limited
by the complexity and low sensitivity of the ELISA protocol and
high minimum calprotectin value detectable in stool. However the
low S. mansoni prevalence in the area may have also affected the
association with the study outcome [16]. With the recent
commercial availability of a new POC calprotectin assay based
upon immunochromatographic dipsticks, this new test format has
greater sensitisation and detection range of calprotectin found in
feces.
The primary objective of the present study was an investigation
of point-of-care (POC) chromatographic FOB detection and fecal
calprotectin with S. mansoni infection status as a proxy for intestinal
morbidity. Secondary objectives were to ascertain their association
with less specific schistosomiasis downstream manifestations such
as anemia and to investigate the short-term changes 24 days after
PZQ treatment.
Methods
Ethics statement
Ethical approval was obtained from both the Liverpool School
of Tropical Medicine and the Uganda National Council of Science
at the Ministry of Health. For all participants information sheets
describing the study were delivered before recruitment. Informed
written consent was obtained from the children’s parents/
guardians and verbal assent from the subjects when possible.
Study population and study setting
The study was conducted as an exit investigation from a large
longitudinal cohort study based in two villages on the Lake Albert
shoreline in Buliisa district, Uganda (Figure 1) during the month
of October 2012 with a follow up survey 24 days later in
November 2012. Children had previously been recruited for a
longitudinal study targeting young children with schistosomiasis
that started in 2009 (Schistosomiasis in Infants and Mothers
(SIMI) cohort) [23]. A total of 216 children were initially surveyed
with 211 of them providing stool and urine at follow-up. Only
Figure 1. Map of the study villages in Buliisa district, Lake
Albert, Uganda.
doi:10.1371/journal.pntd.0002542.g001
Author Summary
The severity of intestinal schistosomiasis, a disease caused
by Schistosoma mansoni infection, is likely under-reported
in part due to the scarcity of field-appropriate morbidity
markers. Downstream potential complications of this
disease include anemia, failure to thrive, and chronic
multi-organ damage. Point-of-care (POC) tools to monitor
intestinal schistosomiasis in low resource settings are
urgently needed to better quantify the burden of disease
in endemic countries and to gauge the clinical impact of
scale-up of preventive PC. For the present study in rural
Uganda, fecal occult blood and fecal calprotectin were
identified as potential surrogate markers of intestinal
morbidity. We tested both POC tests and found that they
were both associated with active schistosomiasis as
detected by eggs in stool with significant decrease in test
positivity after PZQ treatment demonstrating short term
morbidity reversion. Calprotectin was a strong indicator of
intestinal inflammation, however, owing to its high per-
test price makes it difficult to scale-up accordingly.
Conversely, fecal occult blood was technically feasible,
low-cost and had optimal performance as a morbidity
marker, hence we strongly advocate for its immediate
inclusion as a monitoring tool for PC programs.
Intestinal Schistosomiasis Point-of-Care Markers
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those children with two stool samples at both time points were
included in the analysis.
Parasitological detection and PZQ treatment
Children provided two stool samples on two consecutive days
and one urine sample. Duplicate stool smears were prepared from
each sample applying the thick Kato-Katz technique for the
detection of S. mansoni and other soil-transmitted helminths. [24].
Means of eggs per gram of stool (epg) were subsequently calculated
from the egg count slide results. Three infection categories
according to WHO standards were considered for intestinal
schistosomiasis [25]: (1–99 epg) or ‘Light’, (100–399) epg or
‘Medium’ and (.400 epg) or ‘Heavy’. A cathodic circulating
antigen (CCA) assay was also employed to detect the presence of S.
mansoni antigen in urine using a commercially available immuno-
chromatographic dipstick (Rapid Medical Diagnostics, Pretoria,
South Africa) [26]. All children after providing stool, were treated
with PZQ at standard dosing of 40 mg/kg regardless of
parasitological results.
Point-of-care tests: Fecal occult blood, fecal calprotectin,
hemoglobin
All children provided a small finger-prick sample (0.5 ml) of
blood for estimation of hemoglobin levels by Hemocue (A¨ngelholm,
Sweden). Anemia was then defined according to age-dependent cut-
off values [27]. An antigen detection rapid diagnostic test for Pf/
non-Pf malaria was also carried out (Standard Diagnostics,
Kyonggi-do, Korea). Children found to be positive were treated
according to standard national treatment guidelines.
A simple chromatographic test was employed for FOB detection
(Mission TestH, Acon Laboratories, San Diego, CA), following the
manufacturer’s instructions. Briefly a small amount of feces was
homogenised in a liquid buffer after collection. Two drops of stool
suspension were applied to a test cassette and results were visually
read after five minutes and categorized as negative (2), trace
(+/2) and positive (+).
A quantitative point-of–care chromatographic immunoassay
was used for the detection of fecal calprotectin (Quantum BlueH,
Alpha laboratories, Hampshire, UK), according to the manufac-
turer’s instructions. Two drops of homogenised stool were applied
inside a plastic cassette that was then inserted into a portable
electronic reader that quantified the intensity of the control and
test reactions to express a numerical value. The cassette reader was
calibrated for each batch of tests. Cut-off values were based on
recent clinical consensus [28]. Values of calprotectin .50 mg/g
were considered positive [19]. Calprotectin values were further
categorised based on findings from clinical gastroenterology
studies [20,28]. Calprotectin values .160 mg/g are considered
within the range of severe intestinal inflammation as seen in
inflammatory bowel disease [28]. Guided by this findings, we then
created sub-categories to explore the relationship of different
inflammatory cut-offs with schistosomiasis; ‘Low’ (51–149 mg/g),
‘Medium’ (150–299 mg/g) and ‘High’ (.300 mg/g), for subse-
quent statistical analysis.
Data entry and analysis
All data was entered into electronic format using EpiDataH (The
EpiData Association Odense, Denmark) and later analysed using
the R statistical package version 2.14.1 (The R Foundation for
Statistical Computing, Vienna, Austria) and Microsoft Excel
(Redmond, WA, US). Arithmetic and geometric mean of Williams
(GMW) were calculated for S. mansoni infection intensity. 95%
confidence intervals (CI) were calculated for percentages by
applying the exact method.
Primary endpoints of interest were FOB and calprotectin
positivity and their association with egg-patent and CCA positive
Table 1. Prevalence (in %) and distribution of infection and morbidities at baseline and follow up (24 days) in 216 children
surveyed in Buliisa district aged 3–9 years old.
Intensity
Baseline (95% CI)
N=184
24 days (95% CI)
N=159 P value‘
Fecal Occult Blood Any 13.1 (8.6–18.8) 8.1 (4.5–13.3) 0.173
Fecal Calprotectin Any 53.4 (46.0–60.7) 47.1 (39.2–55.2) 0.281
Low 36.5 (29.6–43.8) 19.4 (13.6–26.5) 0.0005
Medium 7.4 (4.1–12.1) 12.6 (7.8–18.7) 0.146
High 9.5 (5.7–14.6) 15.1 (9.9–21.6) 0.137
S. mansoni (Kato-Katz)* Any 63.5 (56.6–70.0) 28.3 (22.0–35.3) ,0.0001
Light 25.1 (19.4–31.5) 17.1 (12.0–23.2) 0.0659
Medium 16.5 (11.8–22.3) 8.5 (4.9–13.5) 0.0234
Heavy 21.8 (16.4–27.9) 2.6 (0.8–6.1) ,0.0001
S. mansoni -CCA** Any 92.8 (88.1–96.1) 88.4 (82.9–92.7) 0.154
S.mansoni Arithmetic mean (epg) Any 408 (281.8–535.2) 93.5 (21.2–165.8) ,0.0001
S.mansoni Geometric mean (epg) Any 28.8 (25.4–30.2) 2.5 (20.8–3.7) ,0.0001
Malaria-RDT Any 80.0 (73.5–85.5) 48.9 (41.3–56.4) ,0.0001
Hemoglobin mean(g/dL) Any 10.9 (7.0–14.7) 11.3 (9.0–14.0) 0.006
Anemia+ Any 56.9 (49.5–64.2) 43.8 (36.5–51.4) 0.016
184 and 154 children had complete parasitological and POC results at baseline and follow up respectively.
*S. mansoni intensities by Kato-Katz: Light: 1–99 epg of stool; Medium: 100–399 egp of stool; Heavy: .400 epg of stool.
**Circulating Cathodic Antigen in urine: includes trace,
+Anemia as defined by WHO standards:Hb,11 gr/dl ( 0–5 years old) Hb,11.5 (5–12 years old) Hb,7 gr/dl-severe anaemia,
‘Differences calculated by fisher exact test and Welch t-test.
doi:10.1371/journal.pntd.0002542.t001
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S. mansoni infection status. After initial exploratory bivariate
analysis, multivariable logistic regression modelling was carried
out using the binomial variables constructed for FOB and
calprotectin as the outcome variables and adjusting for possible
confounding variables such as malaria, anemia, sex, age and
village location. A separate analysis was also performed for
different calprotectin intensity values. Odds ratios (OR) and 95%
CI and P-values were calculated as measures of association
between each variable and the outcomes. P-values,0.05 were
considered statistically significant.
Results
In total, 52.5% of the children surveyed were females. The
mean age was 5.9 with a range (3–9). Further age categories were
created, distinguishing between school age children (6–9 years old)
and preschool age children (3–5 years old).
General characteristics of the study population are summarized
in Table 1. 159 children (84.1%) of the initial 189 with complete
records at baseline had calprotectin results at the 24 days follow-up
survey. For FOB, 171 children (90%) were followed up out of the
190 initially tested at baseline. Due to the low prevalence of other
helminthic STH infections (,0.5%), these were not included in the
analysis. Malaria was highly prevalent in the area with over 80% of
children infected at baseline on the basis of rapid diagnostic testing.
Overall, there was a high prevalence of egg-patent intestinal
schistosomiasis in the area at baseline (63.5%) with almost 22% of
children harbouring heavy intensity infections. By CCA test, S.
mansoni prevalence reached 93% of the children surveyed. As
expected, older children (.5 years old) showed a higher
prevalence of S. mansoni infection than younger children (3–5
years old) (67.2% vs 57.9% with higher infection intensities). S.
mansoni infection dynamics as assessed by microscopy and CCA
testing are shown in Fig. 2.
Association between FOB, calprotectin and S. mansoni
infection before and after treatment (Table 2 and
Figure 3)
Children were stratified by S. mansoni infection status at
baseline (as assessed by Kato-Katz or CCA test) and the
percentage of children positive for FOB and calprotectin in each
group was determined both at baseline and 24 days post PZQ
treatment (Table 2). The results showed that in the group which
was egg patent at baseline, there was a significant decrease in
numbers of individuals who were FOB or calprotectin positive 24
days after treatment. This was particularly evident for children
with medium intensity infections (for calprotectin P=0.035) and
heavy intensity infections (for FOB P=0.007, and calprotectin
P=,0.0001).
Figure 2. Percent of children positive for the different S.mansoni diagnostic tests (Kato-Katz, CCA) as well as stool point-of-care tests
(FOB and calprotectin). The decline in Kato-Katz positivity was significant 24 days after treatment.
doi:10.1371/journal.pntd.0002542.g002
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Association between FOB and S. mansoni infection
(Table 3)
All children with positive FOB were found to be S. mansoni egg
positive at baseline and therefore S. mansoni was not included in the
baseline analysis. After adjusting for potential confounders (age,
sex, anemia, malaria) at follow up there was a very strong
association between FOB and S. mansoni medium and heavy
infection (OR: 6.6 P=0.033, OR: 51.3 P=0.003). Children with
anemia were very likely to have a positive FOB test result, but only
at baseline (OR: 9.2, P=0.036) and girls were more likely to be
FOB positive at follow up (OR: 3.7, P=0.057). Residents from
Walukuba village were more likely to be FOB positive at baseline
(OR: 7.5, P=0.02), however the effect was significantly reversed at
follow up (OR: 0.16, P=0.03).
Association between fecal calprotectin and S. mansoni
infection (Table 4)
Four different models were constructed after bivariate explora-
tion of the possible associations between fecal calprotectin and
S. mansoni infection. When calprotectin positivity (.50 mg/g) was
considered as a binomial outcome, an association was found at
baseline between CCA test positivity, younger age (3–5 years old)
and residency in Bugoigo village. These associations, except for the
village effect, were not seen 24 days after PZQ treatment.
When stratified by calprotectin intensity, ‘Medium’ intensity
(150–299 mg/g) strongly correlated with egg-patent S. mansoni
infection at baseline (OR: 12.5, P=0.05) and follow up (OR: 6.8,
P=0.02), as well as with FOB positivity at baseline (OR: 7.5,
P=0.05). Before PZQ treatment, younger children (3–5 years
old) had significantly increased levels of ‘Light’ intensity (51–
149 mg/g) fecal calprotectin (OR: 2.4, P=0.03) as well as
increased ‘Medium’ intensity calprotectin at follow up (OR:
4.1, P=0.03). FOB at follow up was associated with ‘Light’
intensity calprotectin in unadjusted analysis (Crude OR: 3.89,
P=0.05) although this was not seen when controlled for potential
confounders. Across all intensities, residents of Bugoigo village
were more likely to have positive fecal calprotectin.
Discussion
In the context of performance of PZQ PC in targeted areas for
control of morbidity associated with schistosomiasis , there is a
growing need for standardized, affordable and non-invasive point-
of-care tests as surrogate markers of disease [4]. Our results
highlight the feasibility and reliability of both FOB and
calprotectin assays as appropriate field-applicable correlates for
intestinal schistosomiasis in young children and could be used to
monitor morbidity in pre- and post-treatment settings. A positive
test may also encourage people to partake in treatment campaigns
as there is a generic need for better health advocacy.
Egg-patent schistosomiasis is highly prevalent in our study area
despite repeated PZQ rounds in the past five years [17]. Indeed
transmission here is known to be intense and the regional hot spot
of disease for over 30 years [17]. We found that infection
significantly correlates with markers of inflammation (calprotectin)
and mucosal bleeding (FOB) and that this had a direct relationship
with intensity of infection. Hence we can infer that intestinal
schistosomiasis is also highly prevalent in the area and its public
health implications remain to be fully appreciated. This is a rather
worrisome result for an area with yearly anti-parasitic treatment
campaigns and may be attributed at least in part, to the non-
inclusion in the programs of pre-school age children that are
known to harbour egg-patent infections [29,30]. This leaves a
large proportion of the infected population untreated despite
recent WHO recommendations to include the under-fives in
schistosomiasis PC programs [29],[23],[31]. Different tools for the
detection of intestinal morbidity have been tested in different
community surveys with mixed results [4]. In Uganda, a
longitudinal study measuring the abdominal circumference ratio
(ACR) in children with distended abdomens showed the
widespread occurrence of a diseased state although with a weak
association with morbidity-related egg-patent schistosomiasis [32].
Abdominal ultrasounds are widely used for hepatic and urinary
schistosomiasis in areas where S. mansoni and S. haematobium are
endemic, but they have little value for intestinal disease detection
[33]. Even in a highly endemic S. mansoni area, hepatic and
Table 2. Total number and percentage (%) of children infected with S. mansoni at baseline (n = 117) and at follow up (n = 45) who
were positive for FOB and calprotectin before and after treatment.
FOB Calprotectin
Infection status at baseline
Baseline Positive
N=25
Follow up Positive
N=14
Baseline Positive
N=101
Follow up Positive
N=75
S. mansoni (Kato-Katz)
Any intensity 25 (100) 8 (57.1)+ 66 (65.3) 24 (32)‘‘
1–99 epg 8 (32) 2 (14.2) 19 (18.8) 17 (22.6)
100–399 epg 4 (16) 4 (28.5) 19 (18.8) 6 (8)&
.400 epg 13 (52) 2 (14.2)‘ 28( 27.7) 1 (1.3)
$
S. mansoni CCA*
Positive 22 (88) 12 (85.7) 14 (13.8) 9 (12)
*Circulating Cathodic Antigen in urine: positives include trace.
+Significant difference in values Oct–November by Fisher exact test P= 0.005;
‘Significant difference in values Oct–November by Fisher exact test P= 0.007;
‘‘Significant difference in values Oct–November by Fisher exact test P=,0.0001;
&Significant difference in values Oct–November by Fisher exact test P= 0.035;
$
Significant difference in values Oct–November by Fisher exact test P=,0.0001.
doi:10.1371/journal.pntd.0002542.t002
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intestinal schistosomiasis may or may not co-exist and this
emphasizes the importance of differentiating both clinical entities.
As a limitation to our study we could not compare the point-of-
care tests that we used with colorectal endoscopy, the gold-
standard diagnostic test for intestinal morbidity, however calpro-
tectin has been widely previously validated in other studies as an
acceptable inflammatory marker against colonoscopy [19,21,28].
Our proxy for morbidity was egg-patent S. mansoni infection.
Infection is different from clinical disease and particularly in
schistosomiasis egg-shedding may decrease with time and treat-
ment, but organ damage from chronic inflammatory response to
tissue trapped eggs is likely to persist. The association between
FOB and Schistosoma infection has been clearly demonstrated
before and it can therefore be considered a good surrogate marker
for intestinal pathology [7–9,15]. The advantages of the FOB
immunochemical test are their relatively low cost ($0.6/test), easy
to use with very little technical expertise required. All tests were
reliable with no tests failing making the invalid test rate negligble.
The associations between Walukuba village and FOB, as well as
between Bugoigo village and calprotection, are intriguing. The
precise disease manifestation associated with a parasitic infection
depends on a complex interplay between the host and parasite. In
recent work, we did not find significant genetic differentiation
between S. mansoni parasite populations from the three villages
included in the present study (Betson et al., under review).
However, there are tribal differences in the human populations
between the three villages with certain tribes more or less
represented in each village, for example most people in Walukuba
belong to the Alur tribe, whereas in Bugoigo and Piida, the
Banyoro and Bugungu tribes are also well-represented. These
differences in local ethnography may least in part explain the
associations between specific morbidity markers and particular
villages.
The intertwined relationship between anemia and schistosomi-
asis is found across species and even in individuals with light
parasitic loads [34],[35]. What remains to be elucidated, however,
Figure 3. Percent of children egg positive for S. mansoniwith positive FOB (A) and calprotectin (B) at baseline and 24 days after PZQ
treatment. Statistically significant values are indicated *.
doi:10.1371/journal.pntd.0002542.g003
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is the attributable fraction of intestinal losses versus other
pathogenic mechanisms such as anemia of inflammation [36].
The burden of anemia in endemic communities leads to poor
school and physical performance, such manifestations that will
spiral down to an overall decreased quality of life and adult
attainment [37,38]. We found an interesting positive association
between FOB and anemia at baseline, even after controlling for
malaria co-infection. This suggests significant amounts of blood
loss per rectum which would be consistent with intestinal
schistosomiasis with high parasitic loads as reported in S. japonicum
endemic settings [7]. The potential confounding effects of other
parasitic infections known to cause intestinal bleeding (i.e.
hookworms) was not of concern in our study site since none were
detected. However hookworm should be considered in other
endemic areas, e.g. in the Lake Victoria setting [16]. Due to
mucosal inflammation and possibly bleeding polyps this presen-
tation would require active clinical intervention [6]. At follow up,
we documented a rapid response to PZQ with decreased overall
FOB positivity in children with S.mansoni at baseline and no
association between FOB and anemia. This is highly suggestive of
effective mucosal healing.
Fecal calprotectin proved useful as an inflammatory marker in
correlation with S. mansoni infection. It is important to note that the
calprotectin range most significantly associated with any intensity
S. mansoni infection (150–299 mg/g), is within the inflammatory
bowel disease detection range and would warrant further
endoscopic work up in industrialized countries [19,28]. This is a
significant finding since not all intestinal schistosomiasis is thought
to be inflammatory in nature and therefore calprotectin detection
could aid in identifying more active cases when used as a disease
severity marker [5,39]. The significant decline in calprotectin levels
after PZQ treatment in children with egg patent S.mansoni at
baseline, also suggests a positive response to anti-parasitic treatment,
strengthening the relationship of the association calprotectin-
schistosomiasis. Young children (,4 years of age) are known to
have higher normal range values of fecal calprotectin. Regardless of
this, the association found in our study between young age and high
calprotectin levels is above the range of physiological parameters for
healthy African children and warrants further investigation [40].
This will help define the inflammation attributable to schistosomi-
asis in infected children. For now, calprotectin is an expensive POC
test ($10/test) and its widespread implementation in PC efforts could
be restrained as a consequence unless outside international donor
support was able to subsidise and reduce substantially the cost per
test. Nevertheless, it provides very valuable clinical information and
it should be considered useful to monitor intestinal disease,
especially within a detailed future research study.
For the purpose of this study, we were able to ascertain a strong
relationship between FOB, calprotectin and moderate and heavy
egg intensities of S. mansoni infection. Even though the number of
positive individuals decreased after PZQ treatment, there was no
overall statistical significance after 24 days. However, when only
children that were S. mansoni egg positive at baseline were
analysed, both FOB and calprotectin did have a significant
decrease and therefore detect an ameloriation response to PZQ
treatment. This indeed suggests a short term mucosal healing
response. A longer follow up would be needed to assess longer
term responses. e.g. 2–3 month period.
What remains to be explored in a larger study, is the correlation
between the different stages of mucosal involvement comparing
POC assays with endoscopy before and after PZQ administration.
This would allow for a clinical staging algorithm for intestinal
schistosomiasis that could guide future community based treat-
ment strategies. Due to its low-cost and ease of use, we advocate
for the immediate integration of FOB as a morbidity monitoring
tool in PC campaigns.
Table 3. Fecal Occult Blood logistic regression models at baseline and at 24 days follow up with Adjusted Odds Ratios (AOR) and
95% confident intervals (CI) of the variables included.
Baseline (N=190) Follow up (N=171)
COR* (95% CI) P value AOR** (95% CI) P value COR* (95% CI) P value AOR (95% CI) P value
School Age (6–9 years) 0.89 (0.3–2.3) 0.83 1.35 (0.5–3.7) 0.55 2.81 (0.7–16.3) 0.15 1.92 (0.4–8.3) 0.36
Female 1.55 (0.6–4.2) 0.39 1.97 (0.7–5.4) 0.19 1.77 (0.5–7.0) 0.40 3.74 (0.9–14.6) 0.05
Schistosoma mansoni*
(Kato-Katz)
Any intensity - - 3.89 (1.2–11.9) 0.01 4.28 (1.3–14.0) 0.01
1–99 epg 1.51 (0.5–4.1) 0.45 - 0.80 (0.2–3.8) 0.78 1.64 (0.3–9.3) 0.57
100–399 epg 0.90 (0.2–2.9) 0.99 - 5.88 (1.6–22.1) 0.008 6.62 (1.1–37.9) 0.03
.400 epg 5.23 (1.9–14.0) 0.0002 - 8.5 (1.3–56.2) 0.02 51.3 (3.7–705.6) 0.003
Schistosoma mansoni (CCA) 2.85 (1.4–5.9) 0.004 2.25 (1.1–4.7) 0.02 1.64 (1–2.7) 0.05 1.78 (1.0–3.0) 0.03
Anemia 13.05 (1.7–99.6) 0.001 9.22 (1.2–73.9) 0.03 1.91 (0.5–7.6) 0.27 1.39 (0.3–5.3) 0.62
Malaria 1.80 (0.4–10.1) 0.57 1.18 (0.5–2.5) 0.64 0.39 (0.08–1.4) 0.16 0.33 (0.07–1.5) 0.15
Walukuba Village 8.92 (2.5–48.4) ,0.0001 7.52 (2.0–27.4) 0.002 0.38 (0.09–1.5) 0.17 0.16 (0.03–0.9) 0.03
Crude Odds Ratios (COR) are also shown.
*COR=Crude Odd Ratio;
**AOR=Adjusted Odd Ratio;
All models were controlled for age, sex, Schistosoma mansoni infection by fecal egg count and urine Cathodic Circulating Antigen (CCA), anemia, malaria infection, fecal
calprotectin and village. Reference groups included preschool age, male, uninfected S. mansoni, negative CCA, Non-anemia, Non-malaria, Bugoigo village.
S. mansoni infection was not included in the baseline model since all FOB positive children were also S. mansoni positive.
doi:10.1371/journal.pntd.0002542.t003
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